Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PRRX1 OE RNA-Seq)

ABSTRACT: Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PRRX1 OE RNA-Seq)

PROVIDER: PRJNA837245 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19171544_1.fastq.gz	Fastqsanger.gz
	SRR19171544_2.fastq.gz	Fastqsanger.gz
	SRR19171545_1.fastq.gz	Fastqsanger.gz
	SRR19171545_2.fastq.gz	Fastqsanger.gz
	SRR19171546_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 96

Similar Datasets

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PRRX1 OE RNA-Seq)

Project description:Triple-negative breast cancer (TNBC) is a heterogeneous disease with limited treatment options. To characterize TNBC heterogeneity and treatment response, we combined functional and molecular profiling with computational analysis tools. Using these approaches, we defined transcriptional, epigenetic, and metabolic subtypes, and identified subtype-driving super-enhancers. Single cell RNA sequencing analyses revealed relative homogeneity of the three major transcriptional subtypes (luminal, basal and mesenchymal) within tumors. We found that mesenchymal TNBCs are more similar to mesenchymal neuroblastoma and rhabdoid tumors than to other TNBC subtypes, and the PRRX1 transcription factor serves as a key driver of these tumors. By directly regulating the transcription of mesenchymal genes, PRRX1 is sufficient for inducing the mesenchymal subtype but is not required for its maintenance.

2023-11-09 | GSE202769 | GEO

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PRRX1 ChIP-Seq)

2023-11-09 | GSE202767 | GEO

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PRRX1 KD RNA-Seq)

2023-11-09 | GSE202768 | GEO

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PRRX1 ChIP-Seq)

Project description:Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PRRX1 ChIP-Seq)

| PRJNA837231 | ENA

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PRRX1 KD RNA-Seq)

Project description:Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PRRX1 KD RNA-Seq)

| PRJNA837246 | ENA

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PDX Methylation)

2023-11-09 | GSE202775 | GEO

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer [ChIP-Seq]

2023-11-10 | GSE232086 | GEO

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer [RNA-Seq]

2023-11-10 | GSE232085 | GEO

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer

Project description:Triple-negative breast cancer (TNBC) is a heterogeneous disease with limited treatment options. To characterize TNBC heterogeneity, we defined transcriptional, epigenetic, and metabolic subtypes, and subtype-driving super-enhancers and transcription factors by combining functional and molecular profiling with computational analyses. Single cell RNA sequencing revealed relative homogeneity of the major transcriptional subtypes (luminal, basal, and mesenchymal) within samples. We found that mesenchymal TNBCs are more similar to mesenchymal neuroblastoma and rhabdoid tumors than to other TNBC subtypes, and the PRRX1 transcription factor is a key driver of these tumors. PRRX1 is sufficient for inducing mesenchymal features in basal but not in luminal TNBC cells via reprogramming cellular super-enhancer landscapes and transcriptome but it is not required for its maintenance and for cellular viability. Our comprehensive, large scale, multi-platform, multi-omics study of both experimental and clinical TNBC is an excellent resource for the scientific and clinical research communities as it opens new venues for future investigations.

2023-01-17 | MSV000091071 | MassIVE

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PDX RNA-Seq)

2023-11-09 | GSE202773 | GEO